In the pursuit of targeted therapies for KRAS-mutant pancreatic cancer, diverse strategies have emerged, each being promising in addressing the challenges posed by this notoriously resistant oncogene. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.